Semaglutide Dosing Guide: Frequency & Personalized Strategies

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is administered once weekly via subcutaneous injection, beginning at 0.25 mg and escalating in incremental steps to a target dose of 2.4 mg. This tiered approach allows the body to adapt while monitoring tolerability and efficacy over approximately 16 to 30 weeks.

Understanding dosing frequency is essential, but equally important is recognizing that individual response to semaglutide varies significantly. Genetic factors, baseline metabolic health, and comorbidities influence how your body responds—making personalized guidance from a qualified provider crucial for optimal outcomes.

Standard Semaglutide Dosing Schedule for Weight Loss

The typical semaglutide weight-loss protocol follows a 16-week titration schedule. Weeks 1–4 start at 0.25 mg weekly; weeks 5–8 increase to 0.5 mg; weeks 9–12 advance to 1 mg; and weeks 13–16 reach 1.7 mg. Some providers extend this to 30 weeks for gradual escalation.

Once-weekly dosing provides consistent GLP-1 receptor activation, helping regulate appetite and blood glucose. The slow escalation minimizes gastrointestinal side effects while allowing metabolic adaptation. Your provider may adjust timing based on your individual tolerance and response profile.

Semaglutide Dosing Framework: From Starting Dose to Maintenance

Below is a clinical overview of the standard dosing progression and key milestones during semaglutide treatment for weight management.

Week Range	Dose (mg)	Key Clinical Goals	Expected Considerations
Weeks 1–4	0.25 mg weekly	Tolerability assessment; appetite baseline	Mild GI effects common; appetite reduction begins
Weeks 5–8	0.5 mg weekly	Dose escalation; gastrointestinal adjustment	Nausea may peak; typically subsides within 2–3 weeks
Weeks 9–12	1.0 mg weekly	Weight loss trajectory evaluation	Increased satiety; energy expenditure changes may occur
Weeks 13–16+	1.7–2.4 mg weekly	Maintenance and efficacy optimization	Plateau assessment; provider review for continuation or adjustment

Factors That Influence Individual Dosing Tolerance

Age, body composition, kidney function, and prior medication history shape how quickly you tolerate dose escalation. Individuals with gastroparesis or a history of pancreatitis require careful provider supervision and may follow a modified schedule.

Genetic variation in GLP-1 receptor expression and related metabolic pathways may also affect dose response. Some patients achieve meaningful weight loss at lower maintenance doses (1.0–1.7 mg), while others benefit from the maximum 2.4 mg dose. Your provider should tailor progression based on clinical response.

Safety, Contraindications, and Who Should Not Take Semaglutide

Semaglutide is not appropriate for patients with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, acute pancreatitis, severe kidney disease, or pregnancy. Baseline thyroid and pancreatic assessment may be warranted before starting.

Weekly dosing requires consistent adherence and storage at 36–46°F. Common side effects—nausea, vomiting, constipation, diarrhea—typically diminish after the first few weeks. Serious risks are rare but include gallbladder complications and retinal changes in advanced diabetes. Always discuss contraindications and monitoring with your healthcare provider.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context on your individual predispositions in key GLP-1 pathway genes (GLP1R rs6923761) and related metabolic regulators (FTO rs9939609, MC4R rs17782313). These genetic markers can support a more informed conversation with your provider about whether semaglutide dosing and response patterns align with your genetic profile.

The genetic test reveals predispositions in peptide metabolism and appetite-regulation pathways, not an exact prediction of your response to semaglutide. Some individuals carry genetic variants associated with stronger GLP-1 sensitivity or altered appetite signaling. Understanding these predispositions should be interpreted alongside your clinical presentation, weight-loss history, and metabolic labs.

When you bring genetic insights to your provider, it contextualizes why standard dosing may need adjustment for your body. A provider can use this information to anticipate tolerance challenges, customize your escalation timeline, and set realistic expectations—ultimately supporting a safer, more personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.